利用合成的 N-十八烷基-D-甘露吡喃胺制备甘露糖化脂质体，以增强蛋白质的胃肠道通透性。
Development of mannosylated liposomes using synthesized N-octadecyl-D-mannopyranosylamine to enhance gastrointestinal permeability for protein delivery.
机构信息
Department of Manufacturing Pharmacy, Faculty of Pharmacy, Mahidol University, 447 Sri-Ayudhya Road, Bangkok, 10400, Thailand.
出版信息
AAPS PharmSciTech. 2012 Jun;13(2):699-706. doi: 10.1208/s12249-012-9788-1. Epub 2012 May 5.
Abstract
The lysozyme (LZ)-entrapped mannosylated liposomes were prepared in this study by the use of N-octadecyl-D-mannopyranosylamine (SAMAN), which had been synthesized in-house and confirmed by characterization with FTIR and NMR. The reactant residues of synthesized SAMAN were found to be less than 1%. The mean sizes, zeta potentials, drug entrapment efficiencies, and loading capacities of all liposomal formulations were in the ranges of 234.7 to 431.0 nm, -10.97 to -25.80 mV, 7.52 to 14.10%, and 1.44 to 2.77%, respectively. The permeability of mannosylated LZ liposomes across Caco-2 cell monolayers was significantly enhanced to about 2.5- and 7-folds over those of conventional liposomes and solution, respectively, which might be due to the role of mannose receptor or mannose-binding protein on the intestinal enterocytes.
摘要
本研究通过使用 N-十八烷基-D-甘露吡喃胺（SAMAN）制备了溶菌酶（LZ）包封的甘露糖化脂质体，SAMAN 是在内部合成的，并通过傅里叶变换红外光谱和核磁共振进行了表征确认。合成的 SAMAN 的反应物残留量被发现小于 1%。所有脂质体制剂的平均粒径、ζ电位、药物包封效率和载药量分别在 234.7 至 431.0nm、-10.97 至-25.80mV、7.52 至 14.10%和 1.44 至 2.77%之间。甘露糖化 LZ 脂质体穿过 Caco-2 细胞单层的通透性显著提高，相对于普通脂质体和溶液分别提高了约 2.5 倍和 7 倍，这可能是由于肠上皮细胞上甘露糖受体或甘露糖结合蛋白的作用。
相似文献
1
Development of mannosylated liposomes using synthesized N-octadecyl-D-mannopyranosylamine to enhance gastrointestinal permeability for protein delivery.利用合成的 N-十八烷基-D-甘露吡喃胺制备甘露糖化脂质体，以增强蛋白质的胃肠道通透性。
AAPS PharmSciTech. 2012 Jun;13(2):699-706. doi: 10.1208/s12249-012-9788-1. Epub 2012 May 5.
2
Enhanced permeability across Caco-2 cell monolayers by specific mannosylating ligand of buserelin acetate proliposomes.醋酸布舍瑞林前体脂质体的特定甘露糖化配体增强了跨Caco-2细胞单层的通透性。
J Liposome Res. 2016;26(1):69-79. doi: 10.3109/08982104.2015.1039030. Epub 2015 May 6.
3
Design of a nanostructured lipid carrier intended to improve the treatment of tuberculosis.一种旨在改善结核病治疗的纳米结构脂质载体的设计。
Drug Des Devel Ther. 2016 Aug 2;10:2467-75. doi: 10.2147/DDDT.S104395. eCollection 2016.
4
Design and statistical modeling of mannose-decorated dapsone-containing nanoparticles as a strategy of targeting intestinal M-cells.甘露糖修饰的含氨苯砜纳米颗粒的设计与统计建模：一种靶向肠道M细胞的策略
Int J Nanomedicine. 2016 Jun 3;11:2601-17. doi: 10.2147/IJN.S104908. eCollection 2016.
5
Permeation enhancer effect of chitosan and chitosan derivatives: comparison of formulations as soluble polymers and nanoparticulate systems on insulin absorption in Caco-2 cells.壳聚糖及其衍生物的渗透促进作用：作为可溶性聚合物和纳米颗粒系统的制剂对Caco-2细胞中胰岛素吸收的比较。
Eur J Pharm Biopharm. 2008 Sep;70(1):270-8. doi: 10.1016/j.ejpb.2008.03.004. Epub 2008 Mar 12.
6
Preparation and evaluation of mannose receptor mediated macrophage targeting delivery system.甘露糖受体介导的巨噬细胞靶向递送系统的制备与评价
J Control Release. 2011 Nov 30;152 Suppl 1:e190-1. doi: 10.1016/j.jconrel.2011.08.082.
7
Phospholipid vesicle-bound lysozyme to enhance permeability in human intestinal cells.磷脂囊泡结合溶菌酶以增强人肠细胞的通透性。
Pharm Dev Technol. 2013 Jul-Aug;18(4):821-7. doi: 10.3109/10837450.2012.700930. Epub 2012 Jul 4.
8
Mathematical modelling of the transport of hydroxypropyl-β-cyclodextrin inclusion complexes of ranitidine hydrochloride and furosemide loaded chitosan nanoparticles across a Caco-2 cell monolayer.羟丙基-β-环糊精包合盐酸雷尼替丁和呋塞米壳聚糖纳米粒跨 Caco-2 细胞单层转运的数学模型。
Int J Pharm. 2012 Jan 17;422(1-2):479-88. doi: 10.1016/j.ijpharm.2011.11.016. Epub 2011 Nov 11.
9
Development of mannosylated liposomes for bioadhesive oral drug delivery via M cells of Peyer's patches.用于经派伊尔结M细胞进行生物黏附性口服给药的甘露糖基化脂质体的研发。
Drug Deliv. 2009 Jul;16(5):289-94. doi: 10.1080/10717540902989738.
10
Characterization and in vitro evaluation of intestinal absorption of liposomes encapsulating zanamivir.载有扎那米韦的脂质体的特性鉴定及其肠吸收的体外评价。
Curr Drug Deliv. 2011 Jul;8(4):392-297. doi: 10.2174/156720111795767915.
引用本文的文献
1
Applications of mannose-binding lectins and mannan glycoconjugates in nanomedicine.甘露糖结合凝集素和甘露聚糖糖缀合物在纳米医学中的应用。
J Nanopart Res. 2022;24(11):228. doi: 10.1007/s11051-022-05594-1. Epub 2022 Nov 4.
2
Fabrication and evaluation of mannose decorated curcumin loaded nanostructured lipid carriers for hepatocyte targeting: hepatoprotective activity in Wistar rats.用于肝细胞靶向的甘露糖修饰姜黄素负载纳米结构脂质载体的制备与评价：Wistar大鼠的肝保护活性
Curr Res Pharmacol Drug Discov. 2022 Jan 13;3:100083. doi: 10.1016/j.crphar.2022.100083. eCollection 2022.
3
Nanoparticles as Carriers of Proteins, Peptides and Other Therapeutic Molecules.作为蛋白质、肽和其他治疗性分子载体的纳米颗粒
Open Life Sci. 2018 Oct 31;13:285-298. doi: 10.1515/biol-2018-0035. eCollection 2018 Jan.
4
Optimization of Polyarginine-Conjugated PEG Lipid Grafted Proliposome Formulation for Enhanced Cellular Association of a Protein Drug.用于增强蛋白质药物细胞结合的聚精氨酸共轭聚乙二醇脂质接枝前体脂质体配方的优化
Pharmaceutics. 2019 Jun 11;11(6):272. doi: 10.3390/pharmaceutics11060272.
5
Strengthening peptide-based drug activity with novel glyconanoparticle.新型糖基纳米粒子增强基于肽的药物活性。
PLoS One. 2018 Sep 27;13(9):e0204472. doi: 10.1371/journal.pone.0204472. eCollection 2018.
6
Design and statistical modeling of mannose-decorated dapsone-containing nanoparticles as a strategy of targeting intestinal M-cells.甘露糖修饰的含氨苯砜纳米颗粒的设计与统计建模：一种靶向肠道M细胞的策略
Int J Nanomedicine. 2016 Jun 3;11:2601-17. doi: 10.2147/IJN.S104908. eCollection 2016.
7
Formulation, Pharmacokinetic, and Efficacy Studies of Mannosylated Self-Emulsifying Solid Dispersions of Noscapine.那可丁甘露糖化自乳化固体分散体的处方、药代动力学及药效学研究
PLoS One. 2016 Jan 12;11(1):e0146804. doi: 10.1371/journal.pone.0146804. eCollection 2016.
8
Ultrasound effects on brain-targeting mannosylated liposomes: in vitro and blood-brain barrier transport investigations.超声对脑靶向甘露糖基化脂质体的影响：体外及血脑屏障转运研究
Drug Des Devel Ther. 2015 Jul 24;9:3885-98. doi: 10.2147/DDDT.S87906. eCollection 2015.
本文引用的文献
1
Characterization and in vitro evaluation of intestinal absorption of liposomes encapsulating zanamivir.载有扎那米韦的脂质体的特性鉴定及其肠吸收的体外评价。
Curr Drug Deliv. 2011 Jul;8(4):392-297. doi: 10.2174/156720111795767915.
2
Influence of microenvironment and liposomal formulation on secondary structure and bilayer interaction of lysozyme.溶菌酶的微环境和脂质体配方对其二级结构和双层相互作用的影响。
Colloids Surf B Biointerfaces. 2010 Feb 1;75(2):501-9. doi: 10.1016/j.colsurfb.2009.09.027. Epub 2009 Sep 26.
3
Probing insulin's secondary structure after entrapment into alginate/chitosan nanoparticles.胰岛素包封于海藻酸盐/壳聚糖纳米颗粒后的二级结构探究
Eur J Pharm Biopharm. 2007 Jan;65(1):10-7. doi: 10.1016/j.ejpb.2006.09.005. Epub 2006 Sep 24.
4
Effect of mannose density on mannose receptor-mediated cellular uptake of mannosylated O/W emulsions by macrophages.
J Control Release. 2006 Aug 28;114(2):193-201. doi: 10.1016/j.jconrel.2006.04.010. Epub 2006 May 9.
5
Effectiveness of submicron-sized, chitosan-coated liposomes in oral administration of peptide drugs.亚微米级壳聚糖包衣脂质体用于口服肽类药物的有效性
Int J Pharm. 2005 Oct 13;303(1-2):160-70. doi: 10.1016/j.ijpharm.2005.06.028.
6
Enhanced intestinal absorption of salmon calcitonin (sCT) from proliposomes containing bile salts.从含有胆盐的前体脂质体中增强鲑鱼降钙素（sCT）的肠道吸收。
J Control Release. 2005 Sep 2;106(3):298-308. doi: 10.1016/j.jconrel.2005.05.016.
7
The lectin-cell interaction and its implications to intestinal lectin-mediated drug delivery.凝集素-细胞相互作用及其对肠道凝集素介导的药物递送的影响。
Adv Drug Deliv Rev. 2004 Mar 3;56(4):459-80. doi: 10.1016/j.addr.2003.10.015.
8
Potentiality of double liposomes containing salmon calcitonin as an oral dosage form.
J Control Release. 2003 May 20;89(3):429-36. doi: 10.1016/s0168-3659(03)00160-3.
9
Differential expression of the murine mannose-binding lectins A and C in lymphoid and nonlymphoid organs and tissues.小鼠甘露糖结合凝集素A和C在淋巴及非淋巴器官和组织中的差异表达。
J Immunol. 2003 Feb 1;170(3):1462-5. doi: 10.4049/jimmunol.170.3.1462.
10
L-MBP is expressed in epithelial cells of mouse small intestine.L-髓鞘碱性蛋白在小鼠小肠的上皮细胞中表达。
J Immunol. 2002 Dec 15;169(12):6945-50. doi: 10.4049/jimmunol.169.12.6945.
Zotero 插件